1. Long‐Term Belatacept Exposure Maintains Efficacy and Safety at 5 Years: Results From the Long‐Term Extension of the BENEFIT Study. Issue 11 (18th September 2013) Authors: Rostaing, L.; Vincenti, F.; Grinyó, J.; Rice, K. M.; Bresnahan, B.; Steinberg, S.; Gang, S.; Gaite, L. E.; Moal, M.‐C.; Mondragón‐Ramirez, G. A.; Kothari, J.; Pupim, L.; Larsen, C. P. Journal: American journal of transplantation Issue: Volume 13:Issue 11(2013) Page Start: 2875 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Long‐Term Exposure to Belatacept in Recipients of Extended Criteria Donor Kidneys. Issue 11 (18th September 2013) Authors: Charpentier, B.; Medina Pestana, J. O.; del C. Rial, M.; Rostaing, L.; Grinyó, J.; Vanrenterghem, Y.; Matas, A.; Zhang, R.; Mühlbacher, F.; Pupim, L.; Florman, S. Journal: American journal of transplantation Issue: Volume 13:Issue 11(2013) Page Start: 2884 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗